Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study

Pembrolizumab, an anti-programmed cell death (PD)-1 monoclonal antibody, is an anticancer agent showing substantial benefit in lung cancer and melanoma treatment. Biliary tract cancer (BTC) has been shown to respond to pembrolizumab; however, no credible data of such treatment outcomes exist. Theref...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang Hoon, Lee, Hee Seung, Lee, Sang Hyub, Woo, Sang Myung, Kim, Dong Uk, Bang, Seungmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355970/
https://www.ncbi.nlm.nih.gov/pubmed/32517311
http://dx.doi.org/10.3390/jcm9061769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355970/
https://www.ncbi.nlm.nih.gov/pubmed/32517311
http://dx.doi.org/10.3390/jcm9061769

Ejemplares similares